Oncosil Medical (OSL) investor relations material

Executive summary

• Q1 FY27 marked a step-change in regulatory and commercial progress: U.S. FDA HDE approval for OncoSil in distal cholangiocarcinoma, sales revenue growth of 45.8% YoY and expansion of manufacturing readiness.

• Priorities include U.S. and Australian launches, growth in established markets, label expansion and commercial production at the Sydney facility.

Financial highlights

• Sales revenue increased 45.8% YoY; customer receipts were $0.47m, down 26.6% YoY from $0.64m.

• Operating cash outflow was $3.075m; cash and cash equivalents ended the quarter at $8.721m, versus $6.476m at 30 June 2026.

• R&D cash payments were $1.29m, up $0.54m QoQ, primarily due to TRIPP-FFX study close-out.

Outlook and guidance

• Planned U.S. commercial launch is in 2H FY27; initial distribution is limited to five academic medical centres in a 30-patient Post-Approval Study, with broader distribution subject to FDA engagement after enrolment.

• Sydney commercial production is targeted by end of 2H FY27, subject to remaining Notified Body approvals; Australian launch is also targeted for FY27, subject to approvals.

• R&D cash outflows are expected to decline from Q2 FY27 as trial activities conclude.

• FY27 milestones include U.S. centre activation, Australian and U.S. launches, and EU submissions or approvals for percutaneous application and FOLFIRINOX label changes.